Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans

American Journal of Tropical Medicine and Hygiene

Volumn 58, Issue 3, 1998, Pages 358-364

  Thuma, Philip E ^a   Olivieri, Nancy F ^b   Mabeza, George F ^c   Biemba, Godfrey ^d   Parry, Dean ^d   Zulu, Stenford ^d   Fassos, Frank F ^b   Mcclelland, Robert A ^b   Koren, Gideon ^b   Brittenham, Gary M ^e   Gordeuk, Victor R ^f  

^a Macha Malaria Research Institute   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Macha Hosp Malaria Res Institute   (Zambia)

^e METROHEALTH MEDICAL CENTER   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; CHLOROQUINE; DEFERIPRONE; DEFEROXAMINE; PLACEBO;

ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; BLOOD SMEAR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFECT; HUMAN; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PARASITEMIA; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; ZAMBIA;

EID: 0031922731     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1998.58.358     Document Type: Article

References (23)

1. Raventos-Suarez C, Pollack S, Nagel RL, 1982. Plasmodium falciparum: inhibition of in vitro growth by desferrioxamine. Am J Trop Med Hyg 31: 919-922.
2. Pollack S, Rossan RN, Davidson DE, Escajadillo A, 1987. Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys. Proc Soc Exp Biol Med 184: 162-164.
3. Gordeuk V, Thuma P, Brittenham GM, Zulu S, Simwanza G, M'Hangu A, Flesch G, Parry D, 1992. Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 79: 308-312.
4. Bunnag D, Poltera AA, Viravan C, Looareesuwan S, Harinasuta KT, Schindlery C, 1992. Plasmodicidal effect of desferrioxamine B in human vivax or falciparum malaria from Thailand. Acta Trop 52: 59-67.
5. Gordeuk VR, Thuma PE, Brittenham GM, Biemba G, Zulu S, Simwanza G, Kalense P, M'Hango A, Parry D, Poltera AA, Aikawa M, 1993. Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 48: 193-197.
6. Gordeuk V, Thuma P, Brittenham GM, McLaren C, Parry D, Backenstose A, Biemba G, Msiska R, Holmes L, McKinley E, Vargas L, Gilkeson R, Poltera AA, 1992. Effect of iron chelator therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 327: 1473-1477.
7. Fritsch G, Jung A, 1986. 14C-desferrioxamine B uptake into erythrocytes infected with Plasmodium falciparum. Z Parasitenkd 72: 709-713.
8. Hershko C, Weatherall JD, 1988. Iron-chelating therapy. Crit Rev Clin Lab Sci 26: 303-345.
9. Brittenham GM, 1992.Development of iron-chelating agents for clinical use. Blood 80: 569-574.
10. Matsui D, Klein J, Hermann CV, Gruneau V, McClelland R, Chung D, St-Louis P, Olivieri N, Koren G, 1991. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 50: 294-298.
11. Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton JW, 1988. Antimalarial properties of orally active iron chelators. Blood 72: 358-361.
12. Hershko C, Theanacho EN, Spira DT, Peter HH, Dobbin P, Hider RC, 1991. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators. Blood 77: 637-643.
13. Hershko C, Gordeuk VR, Thuma PE, Theanacho EN, Spira DT, Hider RC, Peto TEA, Brittenham GM, 1992. The antimalarial effect of iron chelators in animal models and in humans with mild falciparum malaria. J Inorg Biochem 47: 267-277.
14. Kontoghiorghes GJ, Sheppard L, 1987. Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpryid-4-ones. Inorg Chim Acta 135: L11-L12.
15. Klein J, Damani LA, Chung D, Epemoulu O, Olivieri N, Koren G, 1991. A high-performance liquid Chromatographic method for the measurement of the iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one in human plasma. Ther Drug Monit 13: 51-54.
16. D'Argenio DZ, Schumitzky A, 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 9: 115-134.
17. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabanichik ZI, 1993. The antimalarial action of desferal involves a direct access route to erythrocytic Plasmodium falciparum parasites. J Clin Invest 91: 218-224.
18. Shanzer A, Libman J, Lytton SD, Glickstein H, Cabantchik ZI, 1991. Reversed siderophores act as antimalarial agents. Proc Natl Acad Sci 88: 6585-6589.
19. Hider RC, Porter JB, Singh S, 1994. The design of therapeutically useful iron chelators. Bergeron RJ, Brittenham GM, eds. The Development of Iron Chehlators for Clinical Use. Boca Raton. FL; CRC Press. 353.
20. Hoffbrand AV, Bartlett AN, Veys PA, O'Connor NTJ, Kontoghiorghes GJ, 1989. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet ii: 457.
21. Berdoukas V, Bentley P, Friost H, Schnebli HP, 1993. Toxicity of oral iron chelator L1. Lancet 341: 1088.
22. Timeus F, Valle P, Crescenzio N, Ruggieri L, Rosso P, Pagliardi GL, Cordero di Montezemelo L, Gabutti V, Ramenghi U, 1994. Effect of desferrioxamine and hydroxypyridones on hemopoietic progenitors and neuroectodermal tumor cells. Am J Hematol 47: 183-188.
23. Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, Hider RC, 1990. Relative oral efficacy and acute toxicity of hydroxypyridinin-4-one iron chelators in mice. Blood 76: 2389-2396.